Absolute bioavailability of ceftriaxone after intramuscular administration to healthy volunteers. 1983

R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino

The disposition and bioavailability of ceftriaxone, a novel cephalosporin, was studied in 7 healthy volunteers after a single 1.5-gram intramuscular administration in comparison with the same dose given by the intravenous route. The plasma levels were measured by means of a high-performance liquid chromatography method up to 48 h after administration. Comparable areas under plasma concentration-time curve (AUC) and biological half-life were obtained proving that ceftriaxone, if assessed by conventional methods, is completely bioavailable when given by the intramuscular route. However, taking into account its nonlinear pharmacokinetics it becomes obvious that direct comparison of AUC values generally leads to a certain overestimation of bioavailability after extravascular administration. This aspect is briefly discussed.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino
October 2002, British journal of clinical pharmacology,
R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino
January 1984, Arzneimittel-Forschung,
R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino
January 1993, Arzneimittel-Forschung,
R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino
December 1987, Arzneimittel-Forschung,
R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino
February 2008, British journal of clinical pharmacology,
R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino
May 1984, Chemical & pharmaceutical bulletin,
R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino
September 1994, Arzneimittel-Forschung,
R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino
January 1986, Giornale di stomatologia e di ortognatodonzia,
R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino
August 2018, Molecules (Basel, Switzerland),
R Delsignore, and C M Baroni, and G Crotti, and F Mineo, and U Butturini, and V Ascalone, and M Cisternino
January 1994, European journal of clinical pharmacology,
Copied contents to your clipboard!